Transplantation

Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors.

Transplantation

Norman DJ, Vincenti F, de Mattos AM, Barry JM, Levitt DJ, Wedel NI, Maia M, Light SE

Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR).

Transplantation

Hariharan S, Adams MB, Brennan DC, Davis CL, First MR, Johnson CP, Ouseph R, Peddi VR, Pelz CJ, Roza AM, Vincenti F, George V

Single-center long-term results of renal transplantation for IgA nephropathy.

Transplantation

Bumgardner GL, Amend WC, Ascher NL, Vincenti FG

Risks associated with conversion of stable patients after liver transplantation to the microemulsion formulation of cyclosporine.

Transplantation

Freise CE, Galbraith CA, Nikolai BJ, Ascher NL, Lake JR, Stock PG, Roberts JP

Immunologic and patient selection strategies for successful utilization of less than 15 kg pediatric donor kidneys--long term experiences with 40 transplants.

Transplantation

Bretan PN, Friese C, Goldstein RB, Osorio RW, Tomlanovich S, Amend W, Mathur V, Vincenti F

A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation.

Transplantation

Vincenti F, Lantz M, Birnbaum J, Garovoy M, Mould D, Hakimi J, Nieforth K, Light S

Pages